NCT01742637View on ClinicalTrials.gov

Study Comparing Adapalene and Benzoyl Peroxide Gel 0.1%/2.5% to Epiduo® and Both to a Placebo Control in the Treatment of Acne Vulgaris

PHASE1CompletedINTERVENTIONAL
Enrollment

2,008

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

February 28, 2014

Study Completion Date

March 31, 2014

Conditions
Acne Vulgaris
Interventions
DRUG

Adapalene and Benzoyl Peroxide Gel 0.1%/2.5%

Adapalene and Benzoyl Peroxide Gel 0.1%/2.5% (Taro Pharmaceuticals Inc.)applied topically once daily for 84 consecutive days.

DRUG

Epiduo® Gel

Epiduo® (Adapalene and Benzoyl Peroxide Gel 0.1%/2.5%) (Galderma Laboratories, L.P.)applied topically once daily for 84 consecutive days.

DRUG

Placebo

Placebo (vehicle of test product) (Taro Pharmaceuticals Inc.)applied topically once daily for 84 consecutive days.

All Listed Sponsors
lead

Sun Pharmaceutical Industries, Inc.

INDUSTRY

NCT01742637 - Study Comparing Adapalene and Benzoyl Peroxide Gel 0.1%/2.5% to Epiduo® and Both to a Placebo Control in the Treatment of Acne Vulgaris | Biotech Hunter | Biotech Hunter